Establishing an Easy-to-Measure Biomarker for the IFN Signature

When it comes to vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), the interferon (IFN) signature represents a therapeutic target that has shown promise. In this study published in Annals of the Rheumatic Diseasesresearchers attempt to find an easy to measure biomarker for the IFN signature. 

In the study, researchers looked at the serum levels of galectin-9, CXCL-10 (IP-10) and tumor necrosis factor receptor type II (TNF-RII) in patients with SLE, SLE+APS and primary APS (PAPS) and healthy controls (n=148) after an initial screening of serum analytes in a smaller cohort (n=43). 

Researchers looked at galectin-9, CXCL-10, and TNF-RII as biomarkers to detect the IFN signature was assessed by receiver operating characteristic curves. 

Results showed that galectin-9, CXCL-10, and TNF-RII were elevated in patients with SLE, SLE+APS and PAPS (p<0.05) and correlated with disease activity and tissue factor expression. “Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS,” the researchers concluded. 

Check out an article on knee osteoarthritis and its link to obesity. 

SOURCE: Annals of the Rheumatic Diseases